If you look at the first studies to show diagnostic accuracy and prognostic value, they were done with Cardiolite® and included women. Subsequent work was done with patients with diabetes, patients with renal failure, and other ethnic groups. If you look at the published literature on diagnosis and prognosis, Cardiolite® was usually there first and covered the full gamut of patients being evaluated.-Manuel Cerqueira, MDCleveland Clinic Foundation, Cleveland, OH
There is only one Cardiolite

Why Cardiolite®?

Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) represents a long-standing commitment to innovation, quality and service for the benefit of healthcare professionals and their patients.

What makes Cardiolite® different? Why do healthcare providers choose Cardiolite®?

Here are just some of the reasons:

Cardiolite® Has a Proud Heritage

Cardiolite® has been approved in the United States for over 17 years. Cardiolite® was the first technetium labeled myocardial perfusion tracer to provide physicians with prognostic information that can be helpful in making patient management decisions related to coronary artery disease.1

Cardiolite® Has Been at the Heart of Nuclear Imaging

The role of Cardiolite® has been crucial in developing nuclear medicine as a specialty and expanding its knowledge base.

Cardiolite® is the subject of more than 10,000 publications2 and was the imaging agent of choice within several post marketing cardiology clinical trials which have resulted in changes in patient care:

  • DIAD3 – patient with diabetes, asymptomatic for coronary artery disease
  • BARI-2D4 – patient with diabetes
  • COURAGE5 – patients with stable angina
  • ERASE6 – patients with unstable angina in an acute setting
  • INSPIRE7 – stable patients post-myocardial infarction
  • IMAGING HF8 – patients with heart failure
Cardiolite is wherever CAD is

Cardiolite® Helps with Making Important Patient Management Decisions

Cardiolite® is the first FDA approved technetium labeled myocardial perfusion agent indicated for developing information for use in patient management decisions.

Patients with normal Cardiolite® study have a <1% chance of having a hard event, cardiac death or myocardial infarction, for the next 12 months9.

For full prescribing information, please visit the prescribing information page.

Click here to view footnotes
  1. Cardiolite® [package insert]. N. Billerica, MA: Lantheus Medical Imaging; 2009.
  2. Medline, Embase, Biosis and Emergency Medicine database search 4/15/08.
  3. DIAD, Young et al. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes
    The DIAD Study: A Randomized Controlled Trial, JAMA. 2009;301:15;1547-55.
  4. BARI-2D, Hypotheses, Design and Methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Am J Cardiol 2006;97(12A):9G-19G.
  5. COURAGE, Boden et al, Optimal Medical Therapy with or without PCI for Stable Coronary Disease; NEJM. 2007;356:1503-16.
  6. ERASE, Myocardial Perfusion Imaging for Evaluation and Triage of Patients with Suspected Acute Cardiac Ischemia, JAMA 2002:228:2693-2700.
  7. INSPIRE, Mahmarian et al, Adenosine SPECT for Assessing Risk After AMI; JACC. 2006;48,12:2448-57.
  8. IMAGING HF, Soman P et al, Etiology and Pathophysiology of new-onset heart failure. Evaluation by myocardial perfusion imaging: JNC 2009, 16:1, 82-91.
  9. Hachamovitch et al, Incremental Prognostic Value of Myocardial Perfusion Single Photon Emission Computed Tomography for the Prediction of Cardiac Death: Differential Stratification for Risk of Cardiac Death and Myocardial Infarction. Circulation 1998;97:535-543.


Lantheus Medical Imaging

Indications and Usage for Cardiolite®:
Myocardial Imaging:  CARDIOLITE® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

None known.


CARDIOLITE® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during CARDIOLITE® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

In studying patients in whom cardiac disease is known or suspected, care should
be taken to assure continuous monitoring and treatment in accordance with safe,
accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering CARDIOLITE®.

Before administering CARDIOLITE® patients should be asked about the possibility of allergic reactions to either CARDIOLITE® or MIRALUMA®.
MIRALUMA® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

Indications and Usage for Thallous Chloride Tl 201 Injection:
Thallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed Tomography) techniques for the diagnosis and localization of myocardial infarction.  It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect.

Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).

It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia.

Thallous Chloride TI 201 is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels.  It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical reexamination.  Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands.


Important Safety Information:
 Following the administration of Thallous Chloride Tl 201  Injection, adverse anaphylactoid reactions have been reported (characterized by cardiovascular, respiratory, and cutaneous symptoms), some severe enough to require treatment.  Hypotension, pruritus, flushing and diffuse rash which responds to antihistamines have been reported.  Other reported events include itching, nausea/vomiting, mild diarrhea, tremor, shortness of breath, chills, fever, conjunctivitis, sweating and blurred vision.

In studying patients in whom myocardial infarction or ischemia is known or suspected, care should be taken to assure continuous clinical monitoring and treatment in accordance with safe, accepted procedure.  Exercise stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation equipment.
The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.

Data are not available concerning the effect of marked alterations in blood glucose, insulin, or pH (such as is found in diabetes mellitus) on the quality of Thallous ­Chloride TI 201 Injection scans.  Attention is directed to the fact that thallium is a potassium analog, and since the transport of potassium is affected by these factors, the possibility exists that the thallium may likewise be affected.


The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Thallous Chloride TI 201 Injection, as all radioactive materials, must be handled with care and used with appropriate safety measures to minimize external radiation exposure to patients and to clinical personnel. 

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Please see full Prescribing Information: Thallous Chloride Tl 201 Injection